SCHEMBL1626427

SCHEMBL1626427

CCOC(=O)C1=C(O)c2ccc(F)cc2C(C)(C)C1=O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 6/20 0.42
MAPT P10636 6/20 0.42
KDM4E B2RXH2 6/20 0.42
MEN1 O00255 5/20 0.42
ALDH1A1 P00352 5/20 0.42
LMNA P02545 5/20 0.42
HPGD P15428 4/20 0.42
ALOX12 P18054 2/20 0.42
NPSR1 Q6W5P4 2/20 0.42
CCR6 P51684 1/20 0.42
HKDC1 Q2TB90 1/20 0.42
KDM4C Q9H3R0 1/20 0.42
SPR P35270 1/20 0.40
TSHR P16473 1/20 0.39
MAPK14 Q16539 1/20 0.39
SMN1; SMN2 Q16637 3/20 0.37
PKM P14618 2/20 0.37
ATM Q13315 2/20 0.37
MCL1 Q07820 1/20 0.37
TDP1 Q9NUW8 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1624395 0.90 SPR (0.45) KMT2AMAPTKDM4EMEN1ALDH1A1
SCHEMBL1626913 0.85 SPR (0.52) KMT2AMAPTKDM4EMEN1ALDH1A1
SCHEMBL1625637 0.85 TDP2 (0.41) KMT2AMAPTKDM4EMEN1ALDH1A1
SCHEMBL1626117 0.85 SPR (0.41) KMT2AMAPTKDM4EMEN1ALDH1A1
SCHEMBL1626423 0.84 ALOX5 (0.39) KMT2AMAPTKDM4EMEN1ALDH1A1
SCHEMBL1626562 0.82 MAPT (0.48) KMT2AMAPTKDM4EMEN1ALDH1A1
SCHEMBL1625313 0.81 SPR (0.46) KMT2AMAPTKDM4EMEN1ALDH1A1
SCHEMBL1626923 0.81 SPR (0.43) KMT2AMAPTKDM4EMEN1ALDH1A1
SCHEMBL1627085 0.81 SPR (0.43) KMT2AMAPTKDM4EMEN1ALDH1A1
SCHEMBL1625783 0.80 SPR (0.46) KMT2AMAPTKDM4EMEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7928139-B2 Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof AMGEN INC. (US) 2011-04-19 US disclosed
US-20100048572-A1 NAPHTHALENONE COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, COMPOSITIONS, AND USES THEREOF AMGEN INC. (US) 2010-02-25 US disclosed
US-7635715-B2 Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof AMGEN INC. (US) 2009-12-22 US disclosed
US-20090093483-A1 Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof AMGEN INC. (US) 2009-04-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100048572-A1 NAPHTHALENONE COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, COMPOSITIONS, AND USES THEREOF EGLN2, EGLN3, HIF1AN KMT2A 1695/4885MAPT 4316/4885KDM4E 977/4885
US-20090093483-A1 Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof EGLN2, EGLN3, HIF1AN KMT2A 1695/4885MAPT 4316/4885KDM4E 977/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.